Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04808453 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of CPI-300 in Patients With Advanced Tumors
A Phase 1 study of Advanced Tumors, sponsored by Coordination Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 4
- Study locations
NCT04808453 is a Phase 1 study of Advanced Tumors that has completed, run by Coordination Pharmaceuticals. The registered enrollment target is 17 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT04808453, a Phase 1 study of Advanced Tumors, has completed, sponsored by Coordination Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a prospective, open-label, single arm, non-randomized study of CPI-300 in patients with advanced tumors. CPI-300 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD).
Conditions Studied
Interventions
- DRUG CPI-300
Study Locations (4)
Arizona
- Honor Health Research Institute - Scottsdale
Florida
- Florida Cancer Specialists - Lake Mary
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04808453
The ClinicalTrials.gov registry entry for NCT04808453 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coordination Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Tumors appearing as the primary indexed condition, and to 1 intervention - of which CPI-300 is the first listed.
NCT04808453 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT04808453 about?
NCT04808453 is a clinical study titled "Phase I Study of CPI-300 in Patients With Advanced Tumors". This is a prospective, open-label, single arm, non-randomized study of CPI-300 in patients with advanced tumors. CPI-300 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD).
What is the current status of trial NCT04808453?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2021-06-15. Estimated completion is 2023-12-15.
What conditions does trial NCT04808453 study?
This clinical trial studies the following conditions: Advanced Tumors.
What interventions are being tested in trial NCT04808453?
The interventions under investigation include: CPI-300 (DRUG).
Who is sponsoring clinical trial NCT04808453?
This trial is sponsored by Coordination Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04808453 being conducted?
This trial has 4 study locations across Arizona, Florida, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.